Autoimmune Hepatitis (AIH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Autoimmune hepatitis (AIH) is a type of liver inflammation that occurs when your immune system attacks liver cells. Although the exact cause of autoimmune hepatitis is unknown, but genetic and environmental factors appear to interact over time to cause the disease. Untreated autoimmune hepatitis can result in liver scarring (cirrhosis) and, eventually to liver failure. When diagnosed and treated early, autoimmune hepatitis can often be controlled with immune-suppressing drugs. When drug treatments for autoimmune hepatitis fail or in cases of advanced liver disease, a liver transplant may be an option.
- The incidence of autoimmune hepatitis (AIH) is estimated at 1-2 per 100,000, and the prevalence is approximately 24 per 100,000.
Thelansis’s “Autoimmune Hepatitis (AIH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autoimmune Hepatitis (AIH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Autoimmune Hepatitis (AIH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Autoimmune Hepatitis (AIH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment